Medicago

About:

Medicago is a biotechnology company focused on the research, development, production, and commercialization of vaccines in Canada.

Website: http://www.medicago.com

Twitter/X: medicagoinc

Top Investors: Fonds de solidarité FTQ, Investissement Quebec, Government of Canada, Yorkville Advisors, CTI Life Sciences Fund

Description:

Medicago Inc., a biotechnology company, focuses on the research, development, production, and commercialization of vaccines in Canada. The company develops its vaccines based on its proprietary technologies, including the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidate includes H5N1 pandemic influenza VLP vaccine, which has completed a Phase I human clinical trial. The company is also developing H1N1 VLP vaccine for Influenza A/California/04/09 virus; and seasonal influenza vaccines. Medicago Inc. has collaboration agreements with Viridis S.A.; Genopole biopark to manufacture pandemic and seasonal influenza vaccines; and Philip Morris International to produce a therapeutic protein with a humancompatible glycosylation pattern. The company was incorporated in 1997 and is headquartered in Quebec City, Canada.